Stay updated on Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.

Latest updates to the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page
- ChecktodayChange DetectedThe website footer now identifies the site as revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check7 days agoChange DetectedThe study record for the daratumumab Phase II trial is available, with details on its design, participant eligibility, treatment, locations, outcome measures, and results. It also includes a study protocol and statistical analysis plan.SummaryDifference53%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA banner announces an NIH terminology transition, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check42 days agoChange DetectedThe footer’s software revision changed from v3.7.0 to v3.7.1; the page still displays a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with a generic error page. This indicates an access restriction rather than changes to the study data.SummaryDifference19%

Stay in the know with updates to Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.